News | August 06, 2024
UK Relonchem receives marketing authorization for Levonorgestrel 1.5 mg Tablets
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy
Norgestrel and Ethinyl Estradiol Tablets USP (RLD Lo/Ovral-28) had an estimated annual sale of USD 34 million in the U.S. (IQVIA MAT Mar 2023)
Subscribe To Our Newsletter & Stay Updated
